FindTrial
Sign In

CONCURRENT RADIOCHEMIOTHERAPHY AND SURGERY IN NSCLC . A PHASE II MULTICENTRIC STUDY

CONCURRENT RADIOCHEMIOTHERAPHY AND SURGERY IN NSCLC . A PHASE II MULTICENTRIC STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-005027-18-IT
Enrollment
Unknown
Registered
2007-08-06
Start date
2005-03-20
Completion date
Unknown
Last updated
2014-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoadiuvant treatment for locally advanced nsclc MedDRA version: 9.1 Level: LLT Classification code 10041068 Term: Small cell lung cancer extensive stage

Interventions

Trade Name: GEMZAR*1FL 200MG POLV Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Gemcitabine CAS Number: 122111-03-9 Concentration unit: mg milligram(s) Concentration type

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: RISPOSTA, TOLLERANZA DISTRETTUALE E SISTEMICA, INDICE DI RESECABILITa' CHIRURGICA, RISPOSTE PATOLOGICHE,VALUTAZIONE COMPLICANZE E RECIDIVE LOCALI O SISTEMICHE EFFETTI COLLATERALI TARDIVI, TEMPO DI PROGRESSIONE ;Secondary Objective: SOPRAVVIVENZA ;Primary end point(s): CLINICAL RESPONSE, FEASIBILITY,RESECABILITY, PATOLOGICAL DOWN STAGING,SIDE EFFECTS,LOCAL AND DISTANCE RECURRENCES, TIME TO PROGRESSION—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026